secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001193125-23-256532
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra: FDA may not approve reproxalap NDA by Nov 23 PDUFA; additional trial needed
--------------------------------------------------------------------------------

- FDA late-cycle review states reproxalap lacks data to support clinical relevance of ocular signs for dry eye.
- FDA indicated Aldeyra needs to conduct an additional clinical trial to satisfy efficacy requirements.
- Based on review timeline, FDA may issue Complete Response Letter and not approve by Nov 23, 2023 PDUFA date.
- Aldeyra submitted responses to mitigate issues, but FDA has not opined on sufficiency and has no obligation to review.
- Reproxalap NDA accepted in Feb 2023; approval now uncertain, requiring more resources and time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312523256532/0001193125-23-256532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312523256532/d760002d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-256532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer